IL17A and psoriasis vulgaris: Additionally, a network meta-analysis (29) comparing the efficacy of over 20 systemic therapies for plaque psoriasis between weeks 8 and 24 found that IL-17A inhibitor resulted in a higher proportion of patients achieving PASI 90 compared to all other interventions, consistent with the findings of this study.